Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer

NCT07646145 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Non-Muscle-Invasive Bladder Cancer (NMIBC)

Interventions

DRUG: Disitamab Vedotin
DRUG: Mitomycin C (MMC)

Sponsor

Shanxi Province Cancer Hospital